SEC
SlamSEC
SearchBrowseEarnings

Aurinia Pharmaceuticals Inc.

Nasdaq:AUPH
Pharmaceutical Preparations·EDMONTON, A0
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

Summary Financials

Aurinia is a genus of flowering plants of the family Brassicaceae (Cruciferae), native to mountainous areas of central and southern Europe, Ukraine, southern European Russia, and Turkey. They are closely related to Alyssum, which they resemble.

CEO
Greenleaf Peter
CFO
Miller Joseph M
Revenue
$175.5M
+31.0% YoY
FY 2025
Adj. EBITDA
-$80.0M
-45.6% margin
FY 2025
Net Income
-$78.0M
-44.5% margin
FY 2025
EPS (Diluted)
-$0.54
FY 2025
Stock Price
$14.37
+0.3%
2026-03-09
52W Range
$6.83 – $16.54
P/E Ratio
-26.6x
Market Cap
$1.9B
Cash
$48.8M
FY 2025
Total Debt
—
Net Cash
$48.8M
FY 2025
Enterprise Value
$1.9B
Debt / EBITDA
0.6x
FY 2025
EV / EBITDA
-23.3x
Employees
—